不同剂量地塞米松联合硼替佐米治疗老年多发性骨髓瘤的疗效和安全性对比分析  

Comparison of the Efficacy and Safety of Different Doses of Dexamethasone Combined with Bortezomib in the Treatment of Elderly Patients with Multiple Myeloma

作　　者：辛鹏亮[1] 林宏峻 许文前[1] 肖慧芳[1] 张金燕 米雪 刁勇[2] 唐明青[2] XIN Peng-liang;LIN Hong-jun;XU Wen-qian;XIAO Hui-fang;ZHANG Jin-yan;MI Xue;DIAO Yong;TANG Ming-qing(Department of Haematology,Quanzhou First Hospital Affiliated to Fujian Medical University,Quanzhou 362000,China;School of medicine,Huaqiao university,Quanzhou 362021,China)

机构地区：[1]福建医科大学附属泉州第一医院血液内科,福建泉州362000 [2]华侨大学医学院,福建泉州362021

出　　处：《海峡药学》2020年第4期116-118,共3页Strait Pharmaceutical Journal

基　　金：福建省科技厅项目(项目号:2019J01070),泉州市科技计划项目(项目号:2018Z012);华侨大学2018年研究生教育教学改革研究项目(18YJG10);华侨大学科研基金资助项目(605-50Y17076)。

摘　　要：目的回顾分析不同剂量地塞米松联合常规剂量硼替佐米治疗多发性骨髓瘤老年患者的临床疗效和安全性。方法以2013年6月~2019年6月期间在我院接受治疗的多发性骨髓瘤老年患者纳入观察对象(共102例),按地塞米松剂量不同分为对照组(大剂量地塞米松)48例与观察组(减低剂量地塞米松)54例。结果观察组与对照组治疗总有效率相当,两组间数据无显著差异(P>0.05);观察组的不良反应发生率明显低于对照组,组间数据差异显著(P<0.05)。结论多发性骨髓瘤老年患者接受减低剂量地塞米松联合常规剂量硼替佐米治疗的疗效确切,且不良反应较少。OBJECTIVE To retrospectively analyze the efficacy and safety of different doses of dexamethasone combined with conventional dose of bortezomib in the treatment of elderly patients with multiple myeloma.METHODS The elderly patients with multiple myeloma treated in our hospital from June 2013 to June 2019 were included in the study(a total of 102 cases).They were divided into the control group(high-dose dexamethasone,48 cases) and the observation group(reduced dose of dexamethasone,54 cases) according to the dose of dexamethasone.RESULTS The objective response rate of treatment in the observation group and the control group was similar,and there was no significant difference between the two groups(P>0.05);The incidence of adverse reactions in the observation group was significantly lower than that in the control group,and the difference between the groups was significant(P<0.05).CONCLUSION Elderly patients with multiple myeloma undergoing reduced-dose dexamethasone combined with conventional doses of bortezomib have definite curative effects and fewer adverse reactions.

关 键 词：多发性骨髓瘤 地塞米松 硼替佐米 疗效 不良反应 

分 类 号：R969.4[医药卫生—药理学]